https://comparerx.org/news/oak-launches-one-hundred-nineteen-dollar-compounded-glp1-plans CompareRx.org en 2026-09-23T08:15:30.664Z Oak launches $119 compounded GLP-1 plans — squeezing cash-pay telehealth weight-loss pricing https://comparerx.org/news/novo-investors-demand-strategy-beyond-semaglutide CompareRx.org en 2026-09-23T04:15:29.177Z Novo faces investor pressure to diversify beyond Wegovy — what it means for US GLP-1 buyers https://comparerx.org/news/haleon-targets-glp1-side-effects-retail-aisles CompareRx.org en 2026-09-23T00:15:52.929Z Haleon targets GLP-1 side effects in CVS aisles — carving out a new cash-pay companion market https://comparerx.org/news/cagrisema-beats-tirzepatide-reimagine-trial CompareRx.org en 2026-09-23T00:15:30.137Z Novo CagriSema beats tirzepatide in REIMAGINE 5 trial — bolstering next-gen GLP-1 competition https://comparerx.org/news/cagrisema-beats-tirzepatide-phase-iii-trial-results CompareRx.org en 2026-09-22T20:15:29.636Z CagriSema beats tirzepatide 5 mg in Phase III trial — redefining the next-gen GLP-1 market https://comparerx.org/news/patients-sue-glp1-makers-naion-vision-loss-telehealth-safety CompareRx.org en 2026-09-22T16:15:27.831Z Patients sue GLP-1 makers over rare NAION vision loss — what safety lawsuits mean for telehealth buyers https://comparerx.org/news/novo-outlines-direct-to-consumer-strategy-obesity-buyers CompareRx.org en 2026-09-21T12:15:27.077Z Novo outlines direct-to-consumer strategy — what it changes for GLP-1 buyers